Macquarie Group’s Vor Biopharma VOR Stock Holding History

Macquarie Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-97	Closed	-$1.95K	–	1910
2024 Q2	$1.95K	Buy	+97	New	+$3.14K	﹤0.01%	1804

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group's VOR Position: Q3 2024 in Review

Macquarie Group sold out of Vor Biopharma (VOR) in Q3 2024, closing a stake of 97 shares — an estimated $1.95K sold.

Macquarie Group first reported a position in VOR in Q2 2024 and held it in 1 quarter. The position peaked at $1.95K in Q2 2024. 54 funds tracked by Wall St. Rank hold VOR as of Q3 2024.

Macquarie Group reported no remaining Vor Biopharma position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 97 Vor Biopharma shares in Q3 2024, an estimated $1.95K.
Macquarie Group first reported a position in Vor Biopharma in Q2 2024 and held it in 1 quarter.
Macquarie Group's Vor Biopharma position peaked at $1.95K in Q2 2024.
54 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.